SCHEMBL140142

SCHEMBL140142

C1COCCSC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18748729 1.00 ALDH1A1 (0.44)
SCHEMBL16877890 0.93
SCHEMBL6203888 0.90
SCHEMBL14116483 0.87
SCHEMBL10505641 0.86 TTR (0.42)
SCHEMBL39457 0.86
SCHEMBL6776258 0.86
SCHEMBL8667852 0.86 TTR (0.42)
SCHEMBL14583489 0.85 ALDH1A1 (0.44)
SCHEMBL19484367 0.84 TTR (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260097015-A1 EXTENDED RELEASE FORMULATIONS COMPRISING SUBSTITUTED INDAZOLE PROPIONIC ACID DERIVATIVE COMPOUNDS AND USES THEREOF PFIZER (US) 2026-04-09 US disclosed
EP-4688750-A1 SUBSTITUTED INDAZOLE PROPIONIC ACID DERIVATIVE COMPOUNDS AND USES THEREOF AS AMPK ACTIVATORS Pfizer Inc. (US) 2026-02-11 EP disclosed
EP-4634169-A1 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF Pfizer Inc. (US) 2025-10-22 EP disclosed
US-12447153-B2 HER2 mutation inhibitors PFIZER INC. (US) 2025-10-21 US disclosed
US-20250235510-A1 COMBINATION THERAPY USING GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONIST COMPOUNDS AND GLP-1 RECEPTOR AGONIST PEPTIDES PFIZER INC. (US) 2025-07-24 US disclosed
US-20250235460-A1 COMBINATION THERAPY USING GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONIST COMPOUNDS AND GLP-1 RECEPTOR AGONIST COMPOUNDS PFIZER INC. (US) 2025-07-24 US disclosed
US-20250109143-A1 KLF2 INDUCING DEUTERATED COMPOUNDS AND USES THEREOF RIPARIAN PHARMACEUTICALS, INC. (US) 2025-04-03 US disclosed
WO-2025032440-A1 KLF2 INDUCING COMPOUNDS AND USES THEREOF PFIZER INC. (US) 2025-02-13 WO disclosed
WO-2024237816-A1 NOVEL AZABICYCLOHEXANE DERIVATIVES ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ПРОМОМЕД РУС" 2024-11-21 WO disclosed
WO-2024209363-A1 SUBSTITUTED INDAZOLE PROPIONIC ACID DERIVATIVE COMPOUNDS AND USES THEREOF AS AMPK ACTIVATORS PFIZER INC. (US) 2024-10-10 WO disclosed
WO-2005013958-A1 HISTONE DEACETYLASE INHIBITORS AS IMMUNOSUPPRESSANTS NOVARTIS AG (CH) 2005-02-17 WO disclosed
WO-2005014574-A1 SUBSTITUTED LACTAMS AND THEIR USE AS ANTI-CANCER AGENTS NOVARTIS AG (CH) 2005-02-17 WO disclosed
US-20050032899-A1 Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination NOVARTIS AG (CH) 2005-02-10 US disclosed
US-6833384-B2 E. g., N-Hydroxy-3-(4-(((2-(1H-indol-3-yl)-ethyl)amino)-amino)methyl)-phenyl)-2E-2 -propenamide; histone deacetylase inhibitors; antiproliferative agents; antitumor agents; anticarcinogenic agents NOVARTIS AG (CH) 2004-12-21 US disclosed
WO-2004037181-A2 GLYCINENITRILE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-05-06 WO disclosed
US-20040024067-A1 Deacetylase inhibitors ATHYRIUM OPPORTUNITIES III ACQUISITION LP 2004-02-05 US disclosed
US-20040014743-A1 2-(Quinolonyl)-fused heterocycles as androgen receptor modulators ORTHO-MCNEIL PHARMACEUTICAL, INC. 2004-01-22 US disclosed
US-6552065-B2 Antiproliferative agents NOVARTIS AG (CH) 2003-04-22 US disclosed
US-20030018062-A1 Deacetylase inhibitors SECURA BIO, INC. 2003-01-23 US disclosed
US-4228252-A STEREOSPECIFIC ADDITIVE OF A SULFIDE AND ETHER COMPOUND ATO CHIMIE (FR) 1980-10-14 US disclosed